[Palliative treatment for colorectal cancer].
Before a decision is made to give a particular drug treatment, first of all the best strategy for the individual patient must be determined. In a patient with an aggressive tumour, for whom a secondary curative approach by means of metastasis resection is not an option, the preferred first-line treatment will generally be a triple combination therapy containing bevacizumab - and this is also true in KRAS/BRAF wild-type patients, since the main aim here is to achieve the longest possible survival time with a minimum of side effects. If an epidermal growth factor receptor (EGFR) antibody (cetuximab or panitumumab) is to be used in first-line or later therapy, then the presence of a KRAS mutation must be excluded beforehand. It is very likely sensible also to exclude a BRAF mutation. Second-line treatment after a first-line therapy containing bevacizumab may be a combination chemotherapy or, in patients who are KRAS wild-type (and possibly also BRAF wild-type), irinotecan plus cetuximab. Locoregional treatments such as chemoembolisation, selective internal radiation therapy (SIRT), and stereotactic
Hegewisch-Becker
Susanna
S
Gemeinschaftspraxis, Hamburg, Deutschland.
Vanhoefer
Udo
U
Kubicka
Stefan
S
Pech
Maciej
M
Moehler
Markus
M
Riess
Hanno
H
Hartmann
Jörg Thomas
JT
Malek
Nisar
N
Rödel
Claus
C
Arnold
Dirk
D
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D004621:Embolization, Therapeutic / Q000639:trends*; D006801:Humans; D010166:Palliative Care / Q000379:methods* / Q000639:trends*; D018714:Radiotherapy, Adjuvant / Q000639:trends*